JP2024510098A5 - - Google Patents
Info
- Publication number
- JP2024510098A5 JP2024510098A5 JP2023550109A JP2023550109A JP2024510098A5 JP 2024510098 A5 JP2024510098 A5 JP 2024510098A5 JP 2023550109 A JP2023550109 A JP 2023550109A JP 2023550109 A JP2023550109 A JP 2023550109A JP 2024510098 A5 JP2024510098 A5 JP 2024510098A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- polypeptide chain
- seq
- heavy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110189359.8 | 2021-02-19 | ||
| CN202110189359 | 2021-02-19 | ||
| PCT/CN2022/076832 WO2022174813A1 (zh) | 2021-02-19 | 2022-02-18 | 抗GPRC5DxBCMAxCD3三特异性抗体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510098A JP2024510098A (ja) | 2024-03-06 |
| JP2024510098A5 true JP2024510098A5 (enExample) | 2025-02-28 |
Family
ID=82932102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023550109A Pending JP2024510098A (ja) | 2021-02-19 | 2022-02-18 | 抗ＧＰＲＣ５ＤｘＢＣＭＡｘＣＤ３三重特異性抗体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250074996A1 (enExample) |
| EP (1) | EP4296286A4 (enExample) |
| JP (1) | JP2024510098A (enExample) |
| CN (1) | CN116897166A (enExample) |
| AU (1) | AU2022223152B2 (enExample) |
| CA (1) | CA3211407A1 (enExample) |
| TW (1) | TWI830151B (enExample) |
| WO (1) | WO2022174813A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022068809A1 (zh) * | 2020-09-29 | 2022-04-07 | 信达生物制药(苏州)有限公司 | 抗cd3抗体以及其用途 |
| WO2022175255A2 (en) | 2021-02-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
| WO2023236889A1 (zh) * | 2022-06-06 | 2023-12-14 | 山东先声生物制药有限公司 | 靶向bcma、gprc5d和t细胞的多特异性抗体及其应用 |
| EP4585615A4 (en) * | 2022-09-09 | 2026-07-08 | Beijing Mabworks Biotech Co Ltd | Multispecific antibody binding to BCMA, GPRC5D and CD3 and its use |
| CN117924485A (zh) * | 2022-10-25 | 2024-04-26 | 上海祥耀生物科技有限责任公司 | 一种抗gprc5d的多特异性抗体 |
| TW202434644A (zh) | 2023-02-07 | 2024-09-01 | 大陸商上海齊魯製藥研究中心有限公司 | 三特異性抗原結合分子及其應用 |
| EP4725970A1 (en) | 2023-06-06 | 2026-04-15 | Fortvita Biologics Inc. | Preparation and use of anti-gprc5d/bcma/cd3 trispecific antibody |
| WO2025056013A1 (zh) * | 2023-09-13 | 2025-03-20 | 江苏恒瑞医药股份有限公司 | 一种包含特异性结合gprc5d和cd3的双特异性抗体的药物组合物 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| AU2024370890A1 (en) | 2023-10-30 | 2026-06-11 | Leads Biolabs Inc. | Antibody binding to bcma and multispecific antibody comprising same |
| CN122349420A (zh) * | 2023-12-04 | 2026-07-07 | 山东先声再明生物制药有限公司 | 一种多特异性抗体的组合物及其制备方法和应用 |
| WO2025134050A1 (en) * | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma |
| WO2025134049A1 (en) * | 2023-12-21 | 2025-06-26 | Janssen Biotech, Inc | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis |
| WO2025131077A1 (zh) * | 2023-12-21 | 2025-06-26 | 上海君实生物医药科技股份有限公司 | 抗cd3多特异性抗体及用途 |
| CN117843788B (zh) * | 2024-01-09 | 2025-02-11 | 四川大学 | 一种抗gprc5d的抗体及其多特异性抗体和相关应用 |
| CN120647761A (zh) * | 2024-03-15 | 2025-09-16 | 信达生物制药(苏州)有限公司 | 抗dll3抗体及其用途 |
| WO2025194478A1 (en) * | 2024-03-22 | 2025-09-25 | Biofront Ltd | Antibodies binding to cd3 and gprc5d, and uses thereof |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2026026893A1 (zh) * | 2024-08-01 | 2026-02-05 | 上海齐鲁制药研究中心有限公司 | 结合人gprc5d/bcma/cd3的三特异性抗体制剂及其用途 |
| WO2026109053A1 (zh) * | 2024-11-25 | 2026-05-28 | 江苏恒瑞医药股份有限公司 | 特异性结合bcma、gprc5d和cd3的抗原结合分子及其医药用途 |
| WO2026119236A1 (zh) * | 2024-12-05 | 2026-06-11 | 信达生物制药(苏州)有限公司 | 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途 |
| WO2026149576A1 (zh) * | 2025-01-13 | 2026-07-16 | 上海橙帆医药有限公司 | 多特异性抗体及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| SG176219A1 (en) * | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
| GB201411320D0 (en) * | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| US10428155B2 (en) * | 2014-12-22 | 2019-10-01 | Xencor, Inc. | Trispecific antibodies |
| EP3297672B1 (en) * | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| GB201522391D0 (en) * | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibody molecules |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| CN109069638B (zh) * | 2016-03-24 | 2022-03-29 | 璟尚生物制药公司 | 用于癌症治疗的三特异性抑制剂 |
| RU2680011C2 (ru) * | 2016-04-29 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
| TWI781108B (zh) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| WO2019005637A2 (en) * | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF |
| CN109970860A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
| TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
| WO2019220368A1 (en) * | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| CN113811546B (zh) * | 2019-05-07 | 2025-03-11 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| CN112062851B (zh) * | 2019-06-11 | 2022-09-09 | 南京驯鹿医疗技术有限公司 | 靶向bcma嵌合抗原受体的抗体及其应用 |
-
2022
- 2022-02-18 US US18/546,862 patent/US20250074996A1/en active Pending
- 2022-02-18 CA CA3211407A patent/CA3211407A1/en active Pending
- 2022-02-18 JP JP2023550109A patent/JP2024510098A/ja active Pending
- 2022-02-18 CN CN202280015788.6A patent/CN116897166A/zh active Pending
- 2022-02-18 AU AU2022223152A patent/AU2022223152B2/en active Active
- 2022-02-18 TW TW111106048A patent/TWI830151B/zh active
- 2022-02-18 WO PCT/CN2022/076832 patent/WO2022174813A1/zh not_active Ceased
- 2022-02-18 EP EP22755586.9A patent/EP4296286A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024175003A5 (enExample) | ||
| CN102906113B (zh) | 治疗性dll4结合蛋白 | |
| JP2024522360A5 (enExample) | ||
| JP2023509448A5 (enExample) | ||
| JP2023538945A5 (enExample) | ||
| JP2021524478A5 (enExample) | ||
| JP2022507487A5 (enExample) | ||
| JP2018108081A5 (enExample) | ||
| RU2009107494A (ru) | АНТИТЕЛА К ErbB2 | |
| JP2019513018A5 (enExample) | ||
| JP2018531219A (ja) | Ｐｄ−ｌ１抗体 | |
| RU2012112340A (ru) | Гуманизированные моноклональные антитела к сеа с созревшей аффинностью | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| RU2015101803A (ru) | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения | |
| CN107530420A (zh) | 抗tim‑3抗体 | |
| JP2020515277A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| JP2021533159A5 (enExample) | ||
| JP2025067915A5 (enExample) | ||
| JP2012532851A5 (enExample) | ||
| RU2019134462A (ru) | Антитела, связывающиеся с steap-1 | |
| JP2023549851A5 (enExample) | ||
| JP2020502233A5 (enExample) | ||
| JP2023506834A5 (enExample) | ||
| JP2024507540A5 (enExample) |